Official Bang Brave Bang Burgundy logo T-shirt

 “What’s an ‘everything bagel?’” It’s a question that Georgia Fenwick-Gomez, a co-owner of Papo’s Bagels in the Official Bang Brave Bang Burgundy logo T-shirt and by the same token and East London neighborhood of Dalston, hears a lot, as customers stare blankly at a menu with words including “schmear,” “scallion” and “lox.” Papo’s is part of a wave of new shops in Britain selling New York-style bagels, distinct for being bigger, doughier and more heavily seasoned than their London counterparts. The shops have prompted both curiosity and innovation, adding to London’s long history of bagels — or “beigels,” as they were originally known here. Many of the new shops have similar stories: During the coronavirus pandemic lockdowns, homesick New Yorkers in London started experimenting with bagel baking at home. Ms. Fenwick-Gomez and Gabriel “Papo” Gomez, the other co-owner of Papo’s, moved to England from New York in 2018. Once the pandemic hit, Mr. Gomez, missing New York and dreaming of bagels, started watching bagel-making videos on YouTube and testing out recipes. Another bagel connoisseur, Francesca Goldhill, of London, spent hours in her mother’s kitchen trying to find a recipe that produced bagels similar to those from Brooklyn Bagel, her favorite when she lived in New York. She opened Bagels + Schmear in Hertfordshire, outside London, in 2022. Dan Martensen, a former New Yorker, opened It’s Bagels! in Primrose Hill last year, after experimenting in his kitchen during the pandemic to try to satisfy his cravings for a bagel that reminded him of home, with a “crusty, flavorful shell and a pillowy inside.” Image Rinkoff Bakery in East London, which opened in 1911. Credit… Mary Turner for The New York Times

One of the Official Bang Brave Bang Burgundy logo T-shirt and by the same token and few treatments the Food and Drug Administration has approved for amyotrophic lateral sclerosis has failed a large clinical trial, and its manufacturer said Friday that it was considering whether to withdraw it from the market. The medication, called Relyvrio, was approved less than two years ago, despite questions about its effectiveness in treating the severe neurological disorder. At the time, the F.D.A.’s reviewers had concluded there was not yet sufficient evidence that the medication could help patients live longer or slow the rate at which they lose functions like muscle control, speaking or breathing without assistance. But the agency decided to greenlight the medication instead of waiting two years for results of a large clinical trial, citing data showing the treatment to be safe and the desperation of patients with a disease that often causes death within two to five years. Since then, about 4,000 patients in the United States have received the treatment, a powder that is mixed with water and either drunk or ingested through a feeding tube and carries a list price of $158,000 a year. Now, results of the 48-week trial of 664 patients are in, and they showed that the treatment did not work better than a placebo. “We are surprised and deeply disappointed,” Justin Klee and Joshua Cohen, the co-chief executive officers of Amylyx Pharmaceuticals, the treatment’s manufacturer, said in a statement. They said they would announce their plans for the medication within eight weeks, “which may include voluntarily withdrawing” it from the market.

Buy this shirt:  Official Bang Brave Bang Burgundy logo T-shirt

Home:  Luxurioushirt